
    
      RCT designed to evaluate the safety and efficacy of L. reuteri DSM17938 administrated to
      newborns babies to modify the fecal microbiome after 30 days of supplementation. Secondary
      Secondary endpoints will be evaluate the occurrence and frequency of AEs Day 0 to Day 60; The
      gut bacterial composition Day 7 and Day 30 as described in primary endpoint; the gut
      bacterial composition in infants born by c-section and supplemented with L. reuteri DSM17938
      compared to the gut bacterial composition in infants born vaginally and the salivary
      concentration of IgA at 48h Â±3h after birth and at Day 30.
    
  